Latest Depression News

Bowen Coking Coal maintained steady production and sales in Q3 2025 while slashing costs by a third through a new mining model, despite ongoing administration and receivership. The company generated positive operating cash flow and advanced key development projects.

WOTSO’s flexspace segment sustained growth in Q4 FY25 with a 4% year-on-year revenue increase, opening four new locations and expanding its footprint by 9%. Occupancy dipped slightly but remains robust at 75%.

TrivarX has reported promising interim results from its US veteran-focused mental health trial using ECG technology, while progressing a strategic acquisition of novel brain tumor imaging IP to broaden its diagnostic portfolio.

An application to the Takeovers Panel questions the integrity of Maronan Metals’ recent $16 million placement and its share purchase plan, raising concerns about undisclosed relationships and share price manipulation.

Coronado Global Resources has filed a detailed SEC Form 8-K revealing confidential discussions with noteholders and outlining its growth trajectory, liquidity management, and operational updates across its Australian and US metallurgical coal assets.

Emyria reports strong revenue growth driven by expanded insurer-funded mental health programs, marking a significant step in national access to evidence-based PTSD and treatment-resistant depression care.

Actinogen Medical has fast-tracked enrolment in its pivotal Alzheimer’s trial, secured a clear FDA regulatory path, and strengthened its financial position with funding extending its runway to mid-2026.

TrivarX has completed recruitment of 60 patients in its US veteran-focused mental health trial, advancing validation of its novel single-lead ECG algorithm for depression screening. Positive interim results from 27 patients set the stage for full data release and commercial discussions.

Actinogen Medical has received approval for an additional $1.87 million research and development tax rebate, bringing its total FY25 rebate to $7.36 million. This funding underpins ongoing clinical trials of its Alzheimer’s and depression therapy candidate, Xanamem.

Actinogen Medical has fast-tracked recruitment in its XanaMIA Alzheimer’s trial, closing pTau biomarker screening early and increasing participant numbers, aiming for final results by mid Q4 2026.

Cogstate Limited reports a record-breaking quarter with sales contracts soaring 88% year-on-year, driven by expanding markets and new therapeutic areas. The company signals continued investment in growth initiatives, including AI and Asia-Pacific expansion, while projecting a strong first half of FY26.

Emyria has secured a multi-year funding extension with Medibank to launch its Empax mental health programs in Brisbane, marking a key step in its national expansion. This insurer-backed initiative aims to improve access to treatment for complex conditions like treatment-resistant depression and PTSD.